和铂医药-B(02142)今日盘中大涨14.11%,引起市场广泛关注。主要原因是和铂医药与科伦博泰就一款抗体新药HBM9378/SKB378达成了价值高达9.7亿美元的海外合作协议。
消息显示,和铂医药与科伦博泰宣布,已就新药HBM9378/SKB378与Windward Bio AG签订了授权协议。Windward Bio获得了该新药在全球大部分地区的独家研发及商业化权利。协议规定,和铂医药与科伦博泰将有权获得总计高达9.7亿美元的首付款和里程碑付款,以及基于净销售额的特许权使用费。包括一笔4500万美元的现金与股权支付。
这笔巨额合作将为和铂医药带来可观的收益,同时HBM9378也有望成为该公司在免疫及过敏疾病领域的重磅新品。市场认为此举将进一步加强和铂医药的长期增长潜力,因此推动股价出现单日大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.